Continuous Glucose Monitoring (CGM) sensors are key components in an artificial pancreas, an emerging tool for type 1 diabetes treatment. Malfunctioning of this component might reduce the efficacy of glucose control achieved by the system and even pose the safety of the patient at risk. Therefore, accurate and prompt detection of these anomalies is an important problem. This paper investigates a model-based method to detect CGM failures. Based on an individualized linear model of the subject, identified on hystorical data, the method predicts future glucose concentration through a one-step ahead Kalman predictor. The correct functioning of the system is then monitored using two different criteria: the first checks the magnitude of prediction residuals. The second checks the whiteness of the residuals through a correlogram test. The effectiveness of the two criteria is investigated and compared by performing tests on an in-silico dataset obtained by means of UVA/Padova Type 1 Diabetes simulator, accepted by the US Food and Drug Administration as a substitute of animal testing prior to artificial pancreas clinical trials on humans.
Detection of Glucose Sensor Faults in an Artificial Pancreas via Whiteness Test on Kalman Filter Residuals
Manzoni, Eleonora
;Rampazzo, Mirco;Favero, Simone Del
2021
Abstract
Continuous Glucose Monitoring (CGM) sensors are key components in an artificial pancreas, an emerging tool for type 1 diabetes treatment. Malfunctioning of this component might reduce the efficacy of glucose control achieved by the system and even pose the safety of the patient at risk. Therefore, accurate and prompt detection of these anomalies is an important problem. This paper investigates a model-based method to detect CGM failures. Based on an individualized linear model of the subject, identified on hystorical data, the method predicts future glucose concentration through a one-step ahead Kalman predictor. The correct functioning of the system is then monitored using two different criteria: the first checks the magnitude of prediction residuals. The second checks the whiteness of the residuals through a correlogram test. The effectiveness of the two criteria is investigated and compared by performing tests on an in-silico dataset obtained by means of UVA/Padova Type 1 Diabetes simulator, accepted by the US Food and Drug Administration as a substitute of animal testing prior to artificial pancreas clinical trials on humans.Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.